A Specialist Breast Care Nurse Role for Women With Metastatic Breast Cancer: Enhancing Supportive Care

Watts, Kaaren; Meiser, Bettina; Conlon, Helen Acree; Rovelli, Susan; Tiller, Kerry; Zorbas, Helen; Lewis, Craig; Neil, Gillian; Friedlander, Michael

doi:10.1188/11.onf.627-631

Cited by 14 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This included caring for the women in the hospital and community. These findings align with, and extend, previous research on a smaller sample (Jones et al 2010, Watts et al 2011. Our findings extend the work of Jones et al (2010) by providing data from a larger sample of BCNs.…”

Section: Discussionsupporting

confidence: 93%

“…Watts et al . () suggest the role includes providing information and emotional support, patient advocacy and liaising with the multidisciplinary team. In a small two‐part study, Jones et al .…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, the definition of the role of the BCN is broad and the nuances of the roles and functions are frequently explored (Amir et al 2004, Yates et al 2007, Paynter et al 2013. Watts et al (2011) suggest the role includes providing information and emotional support, patient advocacy and liaising with the multidisciplinary team. In a small two-part study, Jones et al (2010) interviewed 18 nurses in Queensland, Australia, and developed six themes from the data and then developed a 59-item survey which they presented to 21 BCNs and 21 other nurses and doctors.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The role of the breast care nurse in patient and family care

Luck

Chok

Scott

et al. 2017

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of the breast care nurse in patient and family care

Luck

Chok

Scott

et al. 2017

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

“…[353]. However, there is a need to identify the active components of interventions and an individual’s preference for different types of interventions to determine what works best for him or her.…”

Section: Resultsmentioning

confidence: 99%

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

et al. 2013

View full text Add to dashboard Cite

IntroductionBreast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice.MethodsMore than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer ‘stem’ cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed summary papers through an iterative process which, following further appraisal from experts and patients, were melded into this summary account.ResultsThe 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes; (6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration, sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and standardisation; and facilitated cross-discipline working.ConclusionsWith resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.

show abstract

“…The 17 item online retrospective survey has been developed for the current study using items adapted from a previous health service evaluation [41] and also based upon expert input from the research team. The survey will be administered once all participants have been recruited to the study.…”

Section: Methodsmentioning

confidence: 99%

How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer

et al. 2012

Self Cite

View full text Add to dashboard Cite

BackgroundGermline BRCA1 and BRCA2 mutation testing offered shortly after a breast cancer diagnosis to inform women’s treatment choices - treatment-focused genetic testing ‘TFGT’ - has entered clinical practice in specialist centers and is likely to be soon commonplace in acute breast cancer management, especially for younger women. Yet the optimal way to deliver information about TFGT to younger women newly diagnosed with breast cancer is not known, particularly for those who were not suspected of having a hereditary breast cancer syndrome prior to their cancer diagnosis. Also, little is known about the behavioral and psychosocial impact or cost effectiveness of educating patients about TFGT. This trial aims to examine the impact and efficiency of two models of educating younger women newly diagnosed with breast cancer about genetic testing in order to provide evidence for a safe and effective future clinical pathway for this service.Design/methodsIn this non-inferiority randomized controlled trial, 140 women newly diagnosed with breast cancer (aged less than 50 years) are being recruited from nine cancer centers in Australia. Eligible women with either a significant family history of breast and/or ovarian cancer or with other high risk features suggestive of a mutation detection rate of > 10% are invited by their surgeon prior to mastectomy or radiotherapy. After completing the first questionnaire, participants are randomized to receive either: (a) an educational pamphlet about genetic testing (intervention) or (b) a genetic counseling appointment at a family cancer center (standard care). Each participant is offered genetic testing for germline BRCA mutations. Decision-related and psychosocial outcomes are assessed over 12 months and include decisional conflict (primary outcome);uptake of bilateral mastectomy and/or risk-reducing salpingo-oophorectomy; cancer-specific- and general distress; family involvement in decision making; and decision regret. A process-oriented retrospective online survey will examine health professionals’ attitudes toward TFGT; a health economic analysis will determine the cost effectiveness of the intervention.DiscussionThis trial will provide crucial information about the impact, efficiency and cost effectiveness of an educational pamphlet designed to inform younger women newly diagnosed with breast cancer about genetic testing. Issues regarding implementation of the trial are discussed.Trial registrationThe study is registered with the Australian and New Zealand Clinical Trials Group (Registration no: ACTRN12610000502033)

show abstract

A Specialist Breast Care Nurse Role for Women With Metastatic Breast Cancer: Enhancing Supportive Care

Cited by 14 publications

References 18 publications

The role of the breast care nurse in patient and family care

The role of the breast care nurse in patient and family care

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer

Contact Info

Product

Resources

About